| Literature DB >> 28286936 |
Yu Jin Kim1, Suk Chon2, Seungjoon Oh2, Jeong-Taek Woo2, Sung Woon Kim2, Sang Youl Rhee2.
Abstract
BACKGROUND/AIMS: Due to recent increases in the disease burden of diabetes mellitus, the Health Insurance Review and Assessment Service (HIRA) of Korea implemented a quality assessment of the treatment of diabetes to improve patient care. The present study was conducted to identify any changes after the implementation of the diabetes quality assessment (DQA).Entities:
Keywords: Diabetes complications; Diabetes mellitus; Endocrinology; Quality improvement; Quality of health care
Mesh:
Substances:
Year: 2017 PMID: 28286936 PMCID: PMC6325451 DOI: 10.3904/kjim.2016.136
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Names, definitions, and formulas of the diabetes quality assessment indicators (yearly measurements)
| Type | Area | Indicator name | Calculation formula | ||
|---|---|---|---|---|---|
| Assessment indicators | Continuity of treatment | Outpatient visit | Proportion of patients who visited more than once per quarter | No. of patients who visited more than once per quarter | × 100 |
| No. of subjects for diabetes quality assessment | |||||
| Continuity of prescription | Proportion of prescription days | ||||
| Prescription | Proportion of duplicated prescriptions with the same ingredient groups | No. of duplicated prescriptions with the same ingredient group | × 100 | ||
| Total no. of prescriptions of hypoglycemic agents | |||||
| Proportion of prescriptions with over four ingredient groups | No. of prescriptions with over four ingredient groups | × 100 | |||
| Total no. of prescriptions of hypoglycemic agents | |||||
| Test[ | Proportion who underwent HbA1c testing | No. of patients who underwent HbA1c test | × 100 | ||
| No. of subjects for diabetes quality assessment | |||||
| Proportion who underwent lipid testing | No. of patients who underwent lipid test | × 100 | |||
| No. of subjects for diabetes quality assessment | |||||
| Proportion who underwent the fundus exam | No. of patients who underwent fundus examination | × 100 | |||
| No. of subjects for diabetes quality assessment | |||||
| Monitoring indicators | Test | Implementation rate of microalbuminuria testing | No. of patients who underwent microalbuminuria test | × 100 | |
| No. of subjects for diabetes quality assessment | |||||
| Prescription | Medication cost per day of prescribed hypoglycemic agents | Total medication cost of prescribed hypoglycemic agents | × 100 | ||
| Total prescription days of hypoglycemic agents | |||||
| Proportion of combined prescriptions that do not adhere for the criteria | No. of combined prescriptions that do not adhere for the criteria | × 100 | |||
| No. of prescriptions with over two ingredient groups of hypoglycemic agents | |||||
HbA1c, glycated hemoglobin.
Calculated including tests (inpatient and outpatient) implemented in other healthcare institutions in the year of assessment (however, for 2 years including previous year of assessment for fundus exam).
Diabetes quality assessment indicators according to sex and use of insulin (continuity of treatment)
| Year | Quarterly visit | Proportion of prescriptions per day | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Insulin | Sex | Insulin | |||||||||
| Male, % | Female, % | Yes, % | No, % | Male, % | Female, % | Yes, % | No, % | |||||
| 2009 | 78.7 | 82.4 | < 0.001 | 85.4 | 79.0 | < 0.001 | 84.6 | 85.4 | < 0.001 | 78.7 | 86.5 | < 0.001 |
| 2010 | 80.0 | 82.2 | 0.012 | 84.6 | 80.0 | < 0.001 | 85.9 | 85.2 | < 0.001 | 79.6 | 87.0 | < 0.001 |
| 2011 | 74.3 | 78.7 | < 0.001 | 85.0 | 73.9 | < 0.001 | 87.5 | 88.2 | < 0.001 | 83.1 | 88.9 | < 0.001 |
| 2012 | 74.7 | 77.8 | < 0.001 | 82.6 | 74.3 | < 0.001 | 86.9 | 86.9 | 0.909 | 79.7 | 88.6 | < 0.001 |
| 2013 | 75.5 | 78.9 | < 0.001 | 84.5 | 75.1 | < 0.001 | 88.3 | 87.8 | < 0.001 | 83.4 | 89.1 | < 0.001 |
| 2014 | 74.7 | 78.5 | < 0.001 | 82.5 | 75.0 | < 0.001 | 86.1 | 87.1 | < 0.001 | 82.6 | 87.4 | < 0.001 |
Statistics were analyzed using a chi-square test.
Diabetes quality assessment indicators according to sex and use of insulin (prescription)
| Year | Over four ingredient groups | Same ingredient groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Insulin | Sex | Insulin | |||||||||
| Male, % | Female, % | Yes, % | No, % | Male, % | Female, % | Yes, % | No, % | |||||
| 2009 | 1.17 | 1.08 | 0.371 | 2.51 | 0.58 | < 0.001 | 0.20 | 0.04 | < 0.001 | 0.02 | 0.16 | < 0.001 |
| 2010 | 1.21 | 1.01 | 0.032 | 1.96 | 0.79 | < 0.001 | 0.15 | 0.06 | 0.004 | 0.02 | 0.14 | 0.001 |
| 2011 | 0.45 | 0.42 | 0.560 | 0.73 | 0.33 | < 0.001 | 0.10 | 0.06 | 0.102 | 0.03 | 0.10 | 0.021 |
| 2012 | 0.52 | 0.35 | 0.006 | 0.89 | 0.26 | < 0.001 | 0.14 | 0.07 | 0.019 | 0.02 | 0.13 | 0.002 |
| 2013 | 0.79 | 0.68 | 0.189 | 1.88 | 0.36 | < 0.001 | 0.11 | 0.10 | 0.664 | 0.00 | 0.14 | < 0.001 |
| 2014 | 1.18 | 0.74 | < 0.001 | 2.14 | 0.59 | < 0.001 | 0.15 | 0.11 | 0.292 | 0.03 | 0.17 | 0.001 |
Statistics were analyzed using a chi-square test.
Diabetes quality assessment indicators according to use of insulin (test)
| Year | HbA1c | Lipid | Fundoscopy | Microalbumin | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes, % | No, % | Yes, % | No, % | Yes, % | No, % | Yes, % | No, % | |||||
| 2009 | 97.2 | 91.9 | < 0.001 | 84.7 | 80.2 | < 0.001 | 49.0 | 27.0 | < 0.001 | 43.0 | 28.6 | < 0.001 |
| 2010 | 97.4 | 93.5 | < 0.001 | 84.3 | 81.8 | 0.012 | 47.3 | 27.9 | < 0.001 | 41.6 | 27.5 | < 0.001 |
| 2011 | 97.6 | 94.5 | < 0.001 | 88.7 | 85.4 | < 0.001 | 64.5 | 40.5 | < 0.001 | 72.1 | 48.2 | < 0.001 |
| 2012 | 98.0 | 94.3 | < 0.001 | 89.7 | 85.9 | < 0.001 | 52.7 | 31.2 | < 0.001 | 78.6 | 53.5 | < 0.001 |
| 2013 | 98.1 | 94.6 | < 0.001 | 87.0 | 84.0 | 0.001 | 53.9 | 32.9 | < 0.001 | 71.4 | 47.7 | < 0.001 |
| 2014 | 98.4 | 95.2 | < 0.001 | 83.2 | 82.9 | 0.732 | 58.4 | 36.1 | < 0.001 | 70.8 | 47.1 | < 0.001 |
Statistics were analyzed using a chi-square test.
HbA1c, glycated hemoglobin.
Figure 1.Differences in the annual diabetes quality assessment indicators according to age group. (A) Proportion of patients visiting more than once per quarter and (B) proportion of prescription days. Proportions of patients who underwent the (C) glycated hemoglobin (HbA1c), (D) lipid, (E) fundoscopy, and (F) microalbuminuria tests. (G) Proportion of prescriptions with over four ingredient groups and (H) the proportion of duplicated prescriptions with the same ingredient group (solid and dotted lines indicate the mean values of the diabetes indicators at tertiary hospitals and clinics in 2013 and tertiary hospitals in 2011, respectively. Because the microalbuminuria test was introduced in 2013, there are no 2011 data). All data were analyzed using the chi-square test, and post hoc analyses were performed using Bonferroni’s correction. T, tertiary hospitals; P, primary care institution (clinic). aStatistically significant differences (< 40 years vs. 40 to 80 years, p < 0.05/3), bStatistically significant differences (40 to 80 years vs. > 80 years, p < 0.05/3), cStatistically significant differences (< 40 years vs. > 80 years, p < 0.05/3).
Figure 2.Differences in the annual diabetes quality assessment indicators according to the treatment department. (A) Proportion of patients visiting more than once per quarter. This indicator was the highest (B) Proportion of prescription days. Proportions of patients who underwent the (C) glycated hemoglobin (HbA1c), (D) lipid, (E) fundoscopy and (F) microalbuminuria tests. (G) Proportion of prescriptions with over four ingredient groups and (H) the proportion of prescriptions with the same ingredient group (solid and dotted lines indicate the mean values of the diabetes indicators at tertiary hospitals and clinics in 2013 and tertiary hospitals in 2011, respectively. Because the microalbuminuria test was introduced in 2013, there are no 2011 data). All data were analyzed using the chi-square test, and post hoc analyses were performed using Bonferroni’s correction. T, tertiary hospitals; P, primary care institution (clinic). aStatistically significant differences (endo vs. endo & others, p < 0.05/3), bStatistically significant differences (endo & others vs. others, p < 0.05/3), cStatistically significant differences (endo vs. others, p < 0.05/3).